Dr. Ryan Sullivan on Treatment Options for Advanced Basal Cell Carcinoma

Ryan J. Sullivan, MD
Published: Friday, Jul 08, 2016


Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses treatment options for patients with advanced basal cell carcinomas.
 
The majority of basal cell carcinomas have a mutation that predicts activity of a pathway. The smoothened gene, when mutated, leads to hyperactivation of the hedgehog pathway, says Sullivan.
 
 There are several approved targeted therapies that block the hedgehog pathway. 

However, for some patients, these therapies do not work forever and patients must be treated with another line of therapy.
 
Immunotherapy is being considered, however there is currently not a lot of data regarding the use of immunotherapy in basal cell carcinoma. It is known that one of the causes of basal cell carcinoma is through UV damage and mutational events in the skin—particularly in the basal layer of skin, says Sullivan.

Through those mutational events, there is likely a high mutational burden that would predict that there might be a response to anti–PD-1 therapies.
 

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses treatment options for patients with advanced basal cell carcinomas.
 
The majority of basal cell carcinomas have a mutation that predicts activity of a pathway. The smoothened gene, when mutated, leads to hyperactivation of the hedgehog pathway, says Sullivan.
 
 There are several approved targeted therapies that block the hedgehog pathway. 

However, for some patients, these therapies do not work forever and patients must be treated with another line of therapy.
 
Immunotherapy is being considered, however there is currently not a lot of data regarding the use of immunotherapy in basal cell carcinoma. It is known that one of the causes of basal cell carcinoma is through UV damage and mutational events in the skin—particularly in the basal layer of skin, says Sullivan.

Through those mutational events, there is likely a high mutational burden that would predict that there might be a response to anti–PD-1 therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x